Ground breaking cancer research finds immune system link

by Susanna Wolz

(Medical Xpress)—Curtin University researchers have found evidence that targeting specific cells in the body can reverse the effects of cancer on the immune system.

Dr Connie Jackaman, Early Career Development Fellow at the Curtin Health Innovation Research Institute (CHIRI), is leading a study focused on the capacity of the immune system in older people to deal with cancers.

The research tracked particular cells within the immune system of young and geriatric mice, finding that deterioration, caused by mimicked conditions of lung cancers, could be reduced by activating other cell types.

Dr Jackaman said that the immune system in elderly people, even those who were healthy, was skewed towards but this could be mediated by targeting 'macrophages', a cell found in the immune system.

"The most important outcome from this study was that activating these restored both age-related and tumour-induced ," Dr Jackaman said.

"That is, we could make elderly cells young again by targeting them in the right way, the outcome of which could have real implications for in the elderly."

Although this is the first research undertaken on this topic, the team are confident these findings will have a positive impact on cancer and mesothelioma treatment.

The article was published in the top journal in the field of and geriatrics, Aging Cell. To read the full research article, please visit http://onlinelibrary.wiley.com/doi/10.1111/acel.12062/pdf

add to favorites email to friend print save as pdf

Related Stories

Study reveals that chemotherapy works in an unexpected way

Apr 04, 2013

It's generally thought that anticancer chemotherapies work like antibiotics do, by directly killing off what's harmful. But new research published online on April 4 in the Cell Press journal Immunity shows that effective chemot ...

Recommended for you

Is genetic instability the key to beating cancer?

4 minutes ago

Cancerous tumors may be poised at the edge of their own destruction, an insight that could help researchers find new, more effective treatments, suggest SFI External Professor Ricard Solé and colleagues in an April 9 paper ...

Phase 3 study may be game-changer for acute myeloid leukemia

3 hours ago

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine ...

User comments